Releases Geral
Nyxoah to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference
AGÊNCIA DE COMUNICAÇÃO Conteúdo de responsabilidade da empresa 29 de fevereiro de 2024
Nyxoah
Nyxoah to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference
Mont-Saint-Guibert, Belgium February 29, 2024, 10:30pm CET / 4:30pm ET Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (Nyxoah or the Company), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference, which takes place March 12 13, 2024.
Olivier Taelman, Nyxoahs Chief Executive Officer, will deliver a corporate presentation on Tuesday, March 12, 2024, at 10:40am ET. A webcast of the presentation will be available in the Events section of Nyxoahs Investor Relations website. The Company will be available for 1×1 meetings with institutional investors.
Nyxoahs Investor Presentation can be accessed on the Shareholder Information section of the Companys Investor Relations page.
About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoahs lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the worlds most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.
Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and U.S. commercialization approval.
For more information, please visit http://www.nyxoah.com/.
Caution CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.
Contact:
Nyxoah
David DeMartino, Chief Strategy Officer
david.demartino@nyxoah.com
+1 310 310 1313
Attachment
A OESP nao e(sao) responsavel(is) por erros, incorrecoes, atrasos ou quaisquer decisoes tomadas por seus clientes com base nos Conteudos ora disponibilizados, bem como tais Conteudos nao representam a opiniao da OESP e sao de inteira responsabilidade da GlobeNewswire
Leia também
-
Releases Geral OKX Publishes 17th Consecutive Proof of Reserves, Highlighting USD22.1 Billion in Primary Assets
28 de março de 2024DUBAI, United Arab Emirates, March 28, 2024 (GLOBE NEWSWIRE) -- OKX, a leading global Web3 technology company and crypto exchange, today announced the release of its late
Saiba Mais -
Releases Geral Um ano da lei: planos de saúde ainda dificultam tratamentos fora do rol da ANS
1 de setembro de 2023DINO DIVULGADOR DE NOTÍCIAS São Paulo, SP–(DINO – 01 set, 2023) – Um ano após a sanção da Lei 14.454/2022, que ampliou a cobertura dos planos de saúde,
Saiba Mais -
Releases Geral Universidade em Hong Kong tem professores gerados por IA
18 de junho de 2024(DINO - 12 jun, 2024) - A Inteligência Artificial há muito tempo deixou de ser coisa de filme de ficção científica para se tornar uma realidade
Saiba Mais